Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from OptiBiotix Health ( (GB:OPTI) ).
OptiBiotix Health plc has announced the issuance of 6,099,135 new options over ordinary shares to its CEO, Stephen O’Hara, as a related party transaction. The options, priced at 16 pence per share, replace previously expired options and are set to vest on December 17, 2025. This strategic move is considered fair and reasonable by independent directors, potentially impacting company operations by aligning executive incentives with shareholder interests.
More about OptiBiotix Health
OptiBiotix Health plc, established in 2012, operates in the life sciences industry focusing on the development of compounds that modify the human microbiome for disease prevention and wellness promotion. The company engages extensively in R&D, collaborating with academic experts to create microbial strains and formulations used in supplements and food products. Their primary market areas include obesity, cardiovascular health, and diabetes, with partnerships with over twenty international companies to integrate their microbiome modulators into various consumable goods.
YTD Price Performance: -28.04%
Average Trading Volume: 474,553
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £18.85M
For a thorough assessment of OPTI stock, go to TipRanks’ Stock Analysis page.
